



10049265 037403
10/049265
JC07 Rec'd PCT/PTO 11 FEB 2002

TRANSMITTAL LETTER TO THE UNITED STATES

ATTORNEY'S DOCKET NUMBER 50572

DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO.
PCT/EP00/07370

INTERNATIONAL FILING DATE
31 July 2000

PRIORITY DATE CLAIMED
9 August 1999

TITLE OF INVENTION: MONOCELLULAR OR MULTICELLULAR ORGANISMS FOR PRODUCING RIBOFLAVIN

APPLICANT(S) FOR DO/EO/US Henning ALTHOEFER, Oskar ZELDER, Jose L. Revuelta DOVAL, Maria Angeles Santos GARCIA,
Hermann SAHM, Klaus-Peter STAHMANN, Ines MAETING

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. /X/ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
 2. / / This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
 3. /X/ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
 4. /x / A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
 5. /X/ A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a./X/ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b./ / has been transmitted by the International Bureau.
 - c./ / is not required, as the application was filed in the United States Receiving Office (RO/USO).
 6. /X/ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
 7. / / Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a./ / are transmitted herewith (required only if not transmitted by the International Bureau).
 - b./ / have been transmitted by the International Bureau.
 - c./ / have not been made; however, the time limit for making such amendments has NOT expired.
 - d./ / have not been made and will not be made.
 8. / / A translation of the amendments to the claims under PCT Article 19(35 U.S.C. 371(c)(3)).
 9. / X / An oath or declaration of the inventor(s)(35 U.S.C. 171(c)(4)).
 - 10./ / A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
- Items 11. to 16. below concern other document(s) or information included:
- 11./ X / An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
 - 12./ x / An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
 - 13./x / A FIRST preliminary amendment.
/ / A SECOND or SUBSEQUENT preliminary amendment.
 - 14./ / A substitute specification.
 - 15./ / A change of power of attorney and/or address letter.
 - 16./x/ Other items or information.
International Search Report
International Preliminary Examination Report

100-1049265
 JC13 Rec'd PCT/PTO 11 FEB 2002

U.S. Appl. No. (If Known) INTERNATIONAL APPLN. NO.
 PCT/EP00/07370

ATTORNEY'S DOCKET NO.
 50572

		CALCULATIONS	PTO USE ONLY
17. /X/ The following fees are submitted			
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):			
Search Report has been prepared by the			
EPO or JPO.....	\$890.00	890.00	
International preliminary examination fee paid to USPTO			
(37 CFR 1.482).....	\$710.00		
No international preliminary examination fee paid to			
USPTO (37 CFR 1.482) but international search fee paid			
to USPTO (37 CFR 1.445(a)(2)).....\$740.00			
Neither international preliminary examination fee			
(37 CFR 1.482) nor international search fee			
(37 CFR 1.445(a)(2)) paid to USPTO\$ 1,040.00			
International preliminary examination fee paid to			
USPTO (37 CFR 1.482) and all claims satisfied pro			
visions of PCT Article 33(2)-(4).....\$100.00			
ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 890.00			
Surcharge of \$130.00 for furnishing the oath or declaration			
later than // 20 // 30 months from the earliest			
claimed priority date (37 CFR 1.492(e)).			
Claims	Number Filed	Number Extra	Rate
Total Claims	19 -20		X\$18.
Indep. Claims	3 -3		X\$84.
Multiple dependent claim(s) (if applicable)			+280.
TOTAL OF ABOVE CALCULATION		=	890.
Reduction of 1/2 for filing by small entity, if applicable.			
Verified Small Entity statement must also be filed			
(Note 37 CFR 1.9, 1.27, 1.28).			
SUBTOTAL		=	890.
Processing fee of \$130. for furnishing the English			
translation later than // 20 // 30 months from the			
earliest claimed priority date (37 CFR 1.492(f)). +			
TOTAL NATIONAL FEE		=	890.
Fee for recording the enclosed assignment (37 CFR 1.21(h)).			
The assignment must be accompanied by an appropriate cover			
sheet (37 CFR 3.28, 3.31) \$40.00 per property = 40.			
TOTAL FEES ENCLOSED		=	\$ 930.00
		Amount to be	
		refunded:	\$
		Charged	\$

a./X/ A check in the amount of \$ 930.00 to cover the above fees is enclosed.

b./ / Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c./X/ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 11-0345. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
 KEIL & WEINKAUF
 1101 Connecticut Ave., N.W.
 Washington, D. C. 20036

SIGNATURE

Herbert B. Keil

NAME

Registration No. 18,967

10049265-032143

J005 Rec'd PCT/PTO 02 MAY 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

ALTHOEFER et al.

Serial No. 10/049,265

Filed: February 11, 2002

For: MONOCELLULAR OR MULTICELLULAR ORGANISMS FOR PRODUCING
RIBOFLAVIN

BOX PCT

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Commissioner of Patents and Trademarks,
Washington, D.C. 20231, on: April 30, 2002

Date of Deposit Herbert B. Keil

Person Making Deposit Herbert B. Keil

Signature April 30, 2002

Date of Signature

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS
UNDER 35 USC § 371

Sir:

The following remarks are in reply to the Notification of Missing Requirements
dated April 11, 2002.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of)
ALTHOEFER et al.) BOX PCT
)
International Application)
PCT/EP 00/07370)
)
Filed: July 31, 2000)
)

For: MONOCELLULAR OR MULTICELLULAR ORGANISMS FOR PRODUCING RIBOFLAVIN

PRELIMINARY AMENDMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

Prior to examination, kindly amend the above-identified application as follows:

IN THE CLAIMS

Kindly amend the claims as shown on the attached sheets.

REMARKS

The claims have been amended to eliminate multiple dependency and to place them in better form for U.S. filing. No new matter is included.

A clean copy of the claims is attached.

Favorable action is solicited.

Respectfully submitted,

KEIL & WEINKAUF

H B Keil

Herbert B. Keil
Reg. No. 18,967

1101 Connecticut Ave., N.W.
Washington, D.C. 20036

(202)659-0100

ALTHOEFER et al., Serial No. 10/049,263

IN THE SPECIFICATION

Replace the sequence listing in the specification on pages 1/3 to 3/3 with the attached revised sequence listing on pages 1-4.

ALTHOEFER et al., Serial No. 10/049,263

REMARKS

Translation of the international application into English

The Notification of Missing Requirements stated that the text in the drawings has not been properly translated. Applicants inspected the submitted translated application. Applicants did not find any text in the drawings which has not been properly translated. Attached is a duplicate set of the drawings, which contain no non-English words or phrases.

Number of claims

The Notification of Missing Requirements stated that the number of claims in the International Applications and the number of claims in the translation are not the same. Applicants inspected the amended international application and the translation. Both have 20 claims. The originally filed international application had 21 claims. The international application was amended at a later stage to contain 20 claims (attached please find the German PCT/IPEA/409, which contains the amended claims 1-20 in German, which corresponds to claims 1-20 as filed with the application). These are the current pending claims.

Processing fee

Applicants do not believe any further fees are necessary since the application as submitted was properly translated.

Sequence Listing

The initially filed application included a Sequence Listing. Applicants herein submit a revised sequence listing including a copy of the computer readable form. The

MILITARY SERVICE RECORD

It is believed that by submitting the present amendment and sequence listing diskette, the application now fully complies with the requirements of 37 CFR 1.821-1.825. Favorable action by the examiner is solicited.

Respectfully submitted,

/s/ Kert

1101 Connecticut Ave., N.W.
Washington, D.C. 20036
(202)659-0100

HBK/DSK/kas

ctgcagcaaa	tcgaggtgat	cgccaacgag	gtggacgtgc	ggcaggacgg	gacctggtgc	60
atccggtacc	gcgacgagtc	cgagcacggg	cacgacaagt	cgcggtcgat	cgcggcgtgc	120
aagcagcgct	ggcaacacct	cgagcccgcg	ccggtgtatt	tctactgcgg	cgatgggata	180
agcgacctga	gcgctgcgaa	ggaatgcgac	ctgctgtttg	cgaagagtgg	caaggacctg	240
atctccttct	gcaagaagca	ggacgttccg	ttccgcgagt	tcaacacttt	tgacgatgtg	300
ctgagcgcgg	tcaagcgcgt	ggtggcgggc	gaggcctctg	tcacggaact	ccaggggggc	360
tccgctgcgt	aagcactgtc	tgcatcagtg	accttggcgg	tagctgcgat	ttgtaactac	420
ctacgtaatt	agtctgtctc	gcgctgcggt	ccagtgttag	gcacgcccc	catgaaaggc	480
agccgtaagc	aattagtaac	ggcctagtag	ggctccgatg	tatgtgctag	cacatgacag	540
cccaacgggt	tgagaagtcc	ggctcgaatc	atttccgcgc	cgagtgggtc	gtgggtggag	600

ccgccccgacc ccttgtcagc gcgggcagtt ggatataagg cagtgggtgt agcaaaagtg 660

agntgcgtgc atttcacgaa gccgagcgca acaacgcaca gacatcagta agcagct 717

atg ggc aag gtg aag gta caa caa ccc atc gtc gag atg gac ggc gac 765
Met Gly Lys Val Lys Val Gln Gln Pro Ile Val Glu Met Asp Gly Asp
1 5 10 15

gaa cag acg cgg atc atc tgg cac ttg atc aag gat cag ctc atc ttc 813
Glu Gln Thr Arg Ile Ile Trp His Leu Ile Lys Asp Gln Leu Ile Phe
20 25 30

ccc tac ttg gac gtg gac ttg aag tac tac gat ctt tcc att gag aac 861
Pro Tyr Leu Asp Val Asp Leu Lys Tyr Tyr Asp Leu Ser Ile Glu Asn
35 40 45

agg gat gcc acc gag gac cgc gtg act gtg gag tct gcg gag gcg acc 909
Arg Asp Ala Thr Glu Asp Arg Val Thr Val Glu Ser Ala Glu Ala Thr
50 55 60

ctc aag tac ggc gtt gcc gtc aag tgt gcg att att acc ccg gac gag 957
Leu Lys Tyr Gly Val Ala Val Lys Cys Ala Ile Ile Thr Pro Asp Glu
65 70 75 80

gcg cgt gtc gag gag ttc ggg ctc aag gag atg tgg aag tct ccc aac 1005
Ala Arg Val Glu Glu Phe Gly Leu Lys Glu Met Trp Lys Ser Pro Asn
85 90 95

ggg acc atc cgg aac atc ctc ggc ggg acc gtc ttc aga gag ccc att 1053
Gly Thr Ile Arg Asn Ile Leu Gly Gly Thr Val Phe Arg Glu Pro Ile
100 105 110

att atc cca agg atc ccc aga ctg gtg ccc ggc tgg aac gag ccg atc 1101
Ile Ile Pro Arg Ile Pro Arg Leu Val Pro Gly Trp Asn Glu Pro Ile
115 120 125

att gtc ggc aga cac gcg ttt ggg gac cag tac aag gcg acc gac gtt 1149
Ile Val Gly Arg His Ala Phe Gly Asp Gln Tyr Lys Ala Thr Asp Val
130 135 140

gtc att cca ggc gag ggc acg ttg aag ctg gtc ttt gaa agc aag gac 1197
Val Ile Pro Gly Glu Gly Thr Leu Lys Leu Val Phe Glu Ser Lys Asp
145 150 155 160

ggg gac aag tcc aag aat ctt gac ctg gag ttc ttt gaa tac ccc aag 1245
Gly Asp Lys Ser Lys Asn Leu Asp Leu Glu Phe Phe Glu Tyr Pro Lys
165 170 175

gat ggc ggt gtt gcc atg acc atgtactaca ccaccgactc gatcaccggc 1296
Asp Gly Gly Val Ala Met Thr
180

tttgccaagt cgagcttcga gttggcggtg caaagaaaga tgccgctata ttcgacaacg 1356

aagaacacga tcttgaagaa gtacgacggc aagtttaagg atattttcga gggcatgtac 1416

ccagcggagt acaaggagaa gtttgaggct gctggcatct ggtatgaaca cagactgatt 1476

gacgatatgg ttgcgcagat gttgaagtcc aagggcggct tcatcattgc catgaagaac 1536

tacgatggtg atgtgcagtc ggacatcgtc gccagggct tcgggtcttt gggctcatg 1596
 acttctgttc ttgtgtctcc agatggaaag accttcgaga gtgaggccgc acatggcact 1656
 gtcacccggc actacagaca gcaccagcag ggcaaggaaa catccaccaa ctctattgcc 1716
 tctatttttg cctggatgcg cgggtattata cacagaggta aggtcgacgg taccacagat 1776
 gtcgtgaagt tcggcgagtt gttggagaag tccaccctgg acacgggtgca ggaggacatc 1836
 atgaccaagg acctagcgtt gattttgggc aagaccgaca gagccagcta tgttaccacg 1896
 gaagagttta tcacagcagt agcgaaccgc ttagcgatgg ctacaagcgt cttttttgtg 1956
 aataagaaaa agcaagcaaa attatagcct aggtgcctg tagcgtctat ttattactag 2016
 tctagcatat ctagcacaag aatatagata ctgagccatc cgcccaggat tacagtcagg 2076
 attccaactt gtaaacctcc ggtggtgctc actcgccgca aattaggtga gcttgccatt 2136
 agtcatccga ggcgcagaat gagtagggtt tatagtaaac ccgggtgctg taacaccaga 2196
 tcccactttt cctggcacag tatttttgcc gacaacggca ctgctaaccg tttctcaact 2256
 acgcgcaata atgtaggtcg cacggtccga tgaaaactaa tgcgcagtag catgacatgg 2316
 aattc 2321

<210> 2

<211> 183

<212> PRT

<213> Ashyba gossypii

<400> 2

Met	Gly	Lys	Val	Lys	Val	Gln	Gln	Pro	Ile	Val	Glu	Met	Asp	Gly	Asp
1				5					10					15	
Glu	Gln	Thr	Arg	Ile	Ile	Trp	His	Leu	Ile	Lys	Asp	Gln	Leu	Ile	Phe
			20					25					30		
Pro	Tyr	Leu	Asp	Val	Asp	Leu	Lys	Tyr	Tyr	Asp	Leu	Ser	Ile	Glu	Asn
		35					40					45			
Arg	Asp	Ala	Thr	Glu	Asp	Arg	Val	Thr	Val	Glu	Ser	Ala	Glu	Ala	Thr
		50				55					60				
Leu	Lys	Tyr	Gly	Val	Ala	Val	Lys	Cys	Ala	Ile	Ile	Thr	Pro	Asp	Glu
65				70						75					80
Ala	Arg	Val	Glu	Glu	Phe	Gly	Leu	Lys	Glu	Met	Trp	Lys	Ser	Pro	Asn
			85						90					95	
Gly	Thr	Ile	Arg	Asn	Ile	Leu	Gly	Gly	Thr	Val	Phe	Arg	Glu	Pro	Ile
			100					105					110		
Ile	Ile	Pro	Arg	Ile	Pro	Arg	Leu	Val	Pro	Gly	Trp	Asn	Glu	Pro	Ile
		115					120					125			

Asp Gly Gly Val Ala Met Thr
180

CLEAN VERSION OF AMENDED CLAIMS OZ 50572

3. A monocellular or multicellular microorganism as claimed in claim 1, which is a fungus.
4. A monocellular or multicellular microorganism as claimed in claim 1, which is a fungus from the genus *Ashbya*.
5. A monocellular or multicellular microorganism as claimed in claim 1, which is a fungus of the species *Ashbya gossypii*.
8. An isocitrate dehydrogenase gene as claimed in claim 6 having an upstream promoter which possesses the nucleotide sequence from nucleotide -661 to -1 as depicted in Fig. 11 (SEQ ID No.1).
9. A gene structure which contains an isocitrate dehydrogenase gene as claimed in claim 6 and also regulatory sequences which are operatively linked to this gene.
10. A vector which contains an isocitrate dehydrogenase gene as claimed in claim 6 or a gene structure which contains an isocitrate dehydrogenase gene.
11. A genetically altered microorganism for the biotechnological production of riboflavin, harboring, in replicatable form, an isocitrate dehydrogenase gene as claimed in claim 6 which is more strongly expressed than in the corresponding microorganism which is not genetically altered and/or whose copy number is increased.
12. A genetically altered microorganism as claimed in claim 11 which harbors a gene structure which contains an isocitrate dehydrogenase gene or a vector which contains an isocitrate dehydrogenase gene.

CLEAN VERSION OF AMENDED CLAIMS OZ 50572

13. A genetically altered microorganism as claimed in claim 11 which harbors an isocitrate dehydrogenase which exhibits a catalytic activity which is increased, and/or an ability to be inhibited by inhibitors which is decreased, as compared with that of the corresponding microorganism which is not genetically altered.
14. A process for the biotechnological production of riboflavin, which comprises using a microorganism as claimed in claim 1.
16. A process as claimed in claim 15, wherein the increase in enzyme activity is achieved by replacing the promoter and/or increasing the gene copy number.
17. A process as claimed in claim 15, wherein the enzymic activity is increased as a result of the catalytic activity of the isocitrate dehydrogenase being increased and/or the ability of the isocitrate dehydrogenase to be inhibited by inhibitors being decreased.
18. (canceled)
19. A process for preparing a microorganism for the biotechnological production of riboflavin, said process comprising using the isocitrate dehydrogenase gene as claimed in claim 6.
20. A process for preparing a microorganism for the biotechnological production of riboflavin, said process comprising using a gene structure or vector which contains an isocitrate dehydrogenase gene as claimed in claim 6.

MARKED VERSION OF AMENDED CLAIMS OZ 50572

3. A monocellular or multicellular microorganism as claimed in claim 1 [or 2], which is a fungus.
4. A monocellular or multicellular microorganism as claimed in claim 1 [any of claims 1 to 3], which is a fungus from the genus Ashbya.
5. A monocellular or multicellular microorganism as claimed in claim 1 [any of claims 1 to 4], which is a fungus of the species Ashbya gossypii.
8. An isocitrate dehydrogenase gene as claimed in claim 6 [or 7] having an upstream promoter which possesses the nucleotide sequence from nucleotide -661 to -1 as depicted in Fig. 11 (SEQ ID No.1).
9. A gene structure which contains an isocitrate dehydrogenase gene as claimed in claim 6 [any of claims 6 to 8] and also regulatory sequences which are operatively linked to this gene.
10. A vector which contains an isocitrate dehydrogenase gene as claimed in claim 6 [any of claims 6 to 8] or a gene structure [as claimed in claim 9] which contains an isocitrate dehydrogenase gene.
11. A genetically altered microorganism for the biotechnological production of riboflavin, harboring, in replicatable form, an isocitrate dehydrogenase gene as claimed in claim 6 [any of claims 6 to 8] which is more strongly expressed than in the corresponding microorganism which is not genetically altered and/or whose copy number is increased.
12. A genetically altered microorganism as claimed in claim 11 which harbors a

MARKED VERSION OF AMENDED CLAIMS OZ 50572

gene structure which contains an isocitrate dehydrogenase gene [as claimed in claim 9] or a vector which contains an isocitrate dehydrogenase gene [as claimed in claim 10].

13. A genetically altered microorganism as claimed in claim 11 [or 12] which harbors an isocitrate dehydrogenase which exhibits a catalytic activity which is increased, and/or an ability to be inhibited by inhibitors which is decreased, as compared with that of the corresponding microorganism which is not genetically altered.
14. A process for the biotechnological production of riboflavin, which comprises using a microorganism as claimed in claim 1 [any of claims 1 to 5 or 11 to 13].
16. A process as claimed in claim 15, wherein the increase in enzyme activity is achieved by replacing the promoter and/or increasing the gene copy number.
17. A process as claimed in claim 15 [or 16], wherein the enzymic activity is increased as a result of the catalytic activity of the isocitrate dehydrogenase being increased and/or the ability of the isocitrate dehydrogenase to be inhibited by inhibitors being decreased.
18. (canceled)
19. [The use of an isocitrate dehydrogenase gene as claimed in any of claims 6 to 8] A process for preparing a microorganism [as claimed in any of claims 1 to 5 and 11 to 13] for the biotechnological production of riboflavin, said process comprising using the isocitrate dehydrogenase gene as claimed in claim 6.

MARKED VERSION OF AMENDED CLAIMS OZ 50572

20. [The use of a gene structure as claimed in claim 9, or of a vector as claimed in claim 10,] A process for preparing a microorganism for the biotechnological production of riboflavin [as claimed in any of claims 1 to 5 and 11 to 13], said process comprising using a gene structure or vector which contains an isocitrate dehydrogenase gene as claimed in claim 6.

CLAIMS AS FILED OZ 50572

1. A monocellular or multicellular microorganism for the biotechnological production of riboflavin, which exhibits an activity of an NAD(P)H-forming enzyme which is higher than that of a wild type of the species *Ashbya gossypii* ATCC 10895.
2. A monocellular or multicellular microorganism as claimed in claim 1, which exhibits an elevated isocitrate dehydrogenase activity.
3. A monocellular or multicellular microorganism as claimed in claim 1, which is a fungus.
4. A monocellular or multicellular microorganism as claimed in claim 1, which is a fungus from the genus *Ashbya*.
5. A monocellular or multicellular microorganism as claimed in claim 1, which is a fungus of the species *Ashbya gossypii*.
6. An isocitrate dehydrogenase gene having a nucleotide sequence which encodes the amino acid sequence given in Fig. 11 (SEQ ID No.2) and its allelic variations.
7. An isocitrate dehydrogenase gene as claimed in claim 6 having the nucleotide nucleotide 1 to nucleotide 1262 as depicted in Fig. 11 (SEQ ID No.1) .
8. An isocitrate dehydrogenase gene as claimed in claim 6 having an upstream promoter which possesses the nucleotide sequence from nucleotide -661 to -1 as depicted in Fig. 11 (SEQ ID No.1).
9. A gene structure which contains an isocitrate dehydrogenase gene as claimed in

CLAIMS AS FILED OZ 50572

- claim 6 and also regulatory sequences which are operatively linked to this gene.
10. A vector which contains an isocitrate dehydrogenase gene as claimed in claim 6 or a gene structure which contains an isocitrate dehydrogenase gene.
 11. A genetically altered microorganism for the biotechnological production of riboflavin, harboring, in replicatable form, an isocitrate dehydrogenase gene as claimed in claim 6 which is more strongly expressed than in the corresponding microorganism which is not genetically altered and/or whose copy number is increased.
 12. A genetically altered microorganism as claimed in claim 11 which harbors a gene structure which contains an isocitrate dehydrogenase gene or a vector which contains an isocitrate dehydrogenase gene.
 13. A genetically altered microorganism as claimed in claim 11 which harbors an isocitrate dehydrogenase which exhibits a catalytic activity which is increased, and/or an ability to be inhibited by inhibitors which is decreased, as compared with that of the corresponding microorganism which is not genetically altered.
 14. A process for the biotechnological production of riboflavin, which comprises using a microorganism as claimed in claim 1.
 15. A process for preparing a riboflavin-producing monocellular or multicellular organism, which comprises using recombinant methods to increase the activity of an NAD(P)H-forming enzyme in comparison to that of a wild type of the species *Ashbya gossypii* ATCC 10895.

CLAIMS AS FILED OZ 50572

16. A process as claimed in claim 15, wherein the increase in enzyme activity is achieved by replacing the promoter and/or increasing the gene copy number.
17. A process as claimed in claim 15, wherein the enzymic activity is increased as a result of the catalytic activity of the isocitrate dehydrogenase being increased and/or the ability of the isocitrate dehydrogenase to be inhibited by inhibitors being decreased.
18. (canceled)
19. A process for preparing a microorganism for the biotechnological production of riboflavin, said process comprising using the isocitrate dehydrogenase gene as claimed in claim 6.
20. A process for preparing a microorganism for the biotechnological production of riboflavin, said process comprising using a gene structure or vector which contains an isocitrate dehydrogenase gene as claimed in claim 6.

FZJ 9909 PCT
Forschungszentrum [Research Center] Jülich
GmbH
BASF Aktiengesellschaft

11.13.2000

Monocellular or multicellular organisms for producing riboflavin

5 The present invention relates to a monocellular or multicellular organism for producing riboflavin.

10 Vitamin B₂, also termed riboflavin, is essential for humans and animals. Vitamin B₂ deficiency results in the appearance of inflammation of the oral and pharyngeal mucosae, tears in the corners of the mouth, pruritus and inflammation in the skin folds, and other skin damage, conjunctivitis, diminished visual acuity and clouding of the cornea. Cessation of growth and decrease in weight can occur in infants and children.
15 Vitamin B₂ is therefore of economic importance, in particular as a vitamin preparation in association with vitamin deficiency and as a feed additive. In addition to this, it is also employed as a foodstuff dye, for example in mayonnaise, ice cream, blancmange, etc.

20 Riboflavin is produced either chemically or microbially. In the chemical methods of production, the riboflavin is as a rule obtained in multistep processes as a pure end-product, with, however, it being
25 necessary also to employ relatively expensive starting materials, such as D-ribose.

The use of microorganisms to produce riboflavin provides an alternative to producing this substance
30 chemically. The microbial production of riboflavin is particularly suitable for use in those cases in which there is no requirement for the substance to be highly pure. This is, for example, the case when the riboflavin is to be used as an additive for animal feed
35 products. In such cases, the microbial production of riboflavin has the advantage that this substance can be obtained in a single-step process. It is also possible

to use renewable raw materials, such as vegetable oils, as starting materials for the microbial synthesis.

The production of riboflavin by fermenting fungi such as *Ashbya gossypii* or *Eremothecium ashbyi* has been disclosed (The Merck Index, Windholz et al., eds. Merck & Co., page 1183, 1983, A. Bacher, F. Lingens, Aug. Chem. 1969, p. 393); however, yeasts, such as *Candida* or *Saccharomyces*, and bacteria, such as *Clostridium*, *Bacillus* and *Corynebacterium*, are also suitable for producing riboflavin.

Furthermore, methods using the yeast *Candida famata* have been described, for example, in US 05231007.

Riboflavin-overproducing bacterial strains have been described, for example, in EP 405370, with the strains having been obtained by transforming the riboflavin biosynthesis genes from *Bacillus subtilis*. However, these prokaryotic genes were unsuitable for a recombinant method for producing riboflavin using eukaryotes such as *Saccharomyces cerevisiae* or *Ashbya gossypii*. For this reason, genes which were specific for riboflavin biosynthesis were isolated, according to WO 93/03183, from a eukaryote, namely from *Saccharomyces cerevisiae*, in order to use them to provide a recombinant method for producing riboflavin in a eukaryotic production organism. However, such recombinant production methods are unsuccessful, or have only limited success, in producing riboflavin if insufficient substrate is provided for the enzymes which are specifically involved in the biosynthesis of the riboflavin.

In 1967, Hanson (Hanson AM, 1967, in Microbial Technology, Peppler, HJ, pp.222-250 New York) found that adding the amino acid glycine increases the formation of riboflavin by *Ashbya gossypii*. However,

5

10

15

20

25

30

We have found that this object is achieved by means of a monocellular or multicellular organism whose enzyme

FZJ 9909 PCT

- 4 -

activity with regard to NAD(P)H formation is higher than that of a wild type of the species *Ashbya gossypii* ATCC10895.

5 The aim of an accelerated intracellular supply of NAD(P)H can be achieved by increasing the activity of an NAD(P)H-forming enzyme or decreasing the activity of an NAD(P)H-consuming enzyme, or else by altering specificity. This can be achieved using the known
10 methods of the strain improvement of organisms. That is, in the simplest case, the corresponding strains can be prepared in accordance with the selection by means of screening which is customary in microbiology. It is also possible to use mutation with subsequent
15 selection. In this connection, the mutation can be performed either using chemical mutagenesis or using physical mutagenesis. Another method is selection and mutation with subsequent recombination. Finally, the organisms according to the invention can be prepared by
20 means of genetic manipulation.

According to the invention, the organism is altered in such a way that it produces NAD(P)H intracellularly in a quantity which is greater than the organism requires
25 for maintaining its metabolism. According to the invention, this increase in the intracellular production of NAD(P)H can preferably be achieved by preparing an organism in which the enzyme activity of isocitrate dehydrogenase is increased. This can be
30 achieved, for example, by increasing substrate turnover by altering the catalytic center, or else by abolishing the effect of enzyme inhibitors. An increase in the enzymic activity of the isocitrate dehydrogenase can also be brought about by increasing synthesis of the
35 enzyme, for example by means of gene amplification or by eliminating factors which repress enzyme biosynthesis.

According to the invention, the activity of the isocitrate dehydrogenase can preferably be increased by mutating the isocitrate dehydrogenase gene. Such mutations can either be produced in a random manner
5 using classical methods, for example using UV irradiation or mutation-inducing chemicals, or specifically, using recombinant DNA methods, such as deletion, insertion and/or nucleotide exchange.

10 Isocitrate dehydrogenase gene expression can be achieved by incorporating isocitrate dehydrogenase gene copies and/or by augmenting regulatory factors which exert a positive influence on isocitrate dehydrogenase gene expression. Thus, regulatory elements can
15 preferably be augmented at the transcriptional level by, in particular, increasing transcriptional signals. However, in addition, it is also possible to augment translation by, for example, improving the stability of the mRNA.

20 In order to increase the gene copy number, the isocitrate dehydrogenase gene can, for example, be incorporated into a gene construct or into a vector which preferably contains regulatory gene sequences
25 which are assigned to the isocitrate dehydrogenase gene, in particular regulatory gene sequences which augment expression of the gene. A riboflavin-producing microorganism is then transformed with the gene construct which contains the isocitrate dehydrogenase
30 gene.

According to the invention, overexpression of the isocitrate dehydrogenase can also be achieved by replacing the promoter. In this connection, it is
35 possible to achieve the higher enzymic activity either by incorporating gene copies or by replacing the promoter. However, it is equally also possible to achieve the desired change in enzyme activity by

simultaneously replacing the promoter and incorporating gene copies.

5 The change in the isocitrate dehydrogenase gene leads to an accelerated formation of NAD(P)H and, at the same time, to a surprisingly large increase, such as was not previously achievable, in the formation of riboflavin.

10 The isocitrate dehydrogenase gene is preferably isolated from microorganisms, particularly preferably from fungi. In this connection, preference is once again given to fungi of the genus *Ashbya*. The species *Ashbya gossypii* is most highly preferred.

15 However, all other organisms whose cells contain the sequence for forming isocitrate dehydrogenase, that is plant and animal cells as well, are also suitable for isolating the gene. The gene can be isolated by homologous or heterologous complementation of a mutant
20 which is defective in the isocitrate dehydrogenase gene or else by means of heterologous probing or PCR using heterologous primers. For subcloning, the insert in the complementing plasmid can subsequently be minimized in size by means of suitable steps using restriction
25 enzymes. After sequencing and identification of the putative gene, there then follows a perfect-fit subcloning by means of PCR. Plasmids which carry the resulting fragments as inserts are introduced into the isocitrate dehydrogenase gene-defective mutant, which
30 is tested for the functionality of the isocitrate dehydrogenase gene. Finally, functional constructs are used for transforming a riboflavin producer.

35 Following isolation and sequencing, the isocitrate dehydrogenase genes can be obtained having nucleotide sequences which encode the given amino acid sequence or its allelic variation. Allelic variations include, in particular, derivatives which can be obtained by

deletion, insertion and substitution of nucleotides from corresponding sequences, with the isocitrate dehydrogenase activity being preserved. A corresponding sequence is given, from nucleotide 1 to nucleotide 5 1262, in Figure 2b.

A promoter having the nucleotide sequence from nucleotide -661 to -1 as shown in Fig. 11, or a DNA sequence which essentially acts in the same manner, is, 10 in particular, placed upstream of the isocitrate dehydrogenase genes. Thus, a promoter which differs from the promoter having the given nucleotide sequence by means of one or more nucleotide exchanges or by insertion and/or deletion, without, however, the 15 functionality or the activity of the promoter being impaired, can, for example, be placed upstream of the gene. Furthermore, the activity of the promoter can be increased by altering its sequence or the promoter can be completely replaced with active promoters.

20 Furthermore, regulatory gene sequences or regulatory genes, which, in particular, increase the activity of the isocitrate dehydrogenase gene, can be assigned to the isocitrate dehydrogenase gene. Thus, what are 25 termed "enhancers", which bring about an increase in isocitrate dehydrogenase expression by means of an improved interaction between the RNA polymerase and DNA, can, for example, be assigned to the isocitrate dehydrogenase gene.

30 One or more DNA sequences can be placed upstream and/or downstream of the isocitrate dehydrogenase gene, with or without a promoter which has been placed upstream, and/or with or without a regulatory gene, such that the 35 gene is contained in a gene structure. By means of cloning the isocitrate dehydrogenase gene, it is possible to obtain plasmids or vectors which contain the isocitrate dehydrogenase gene and which are

suitable for transforming a riboflavin producer. The cells which can be obtained by transformation harbor the gene in replicatable form, i.e. in additional copies on the chromosome, with the gene copies being
5 integrated by means of homologous recombination at arbitrary sites on the genome, and/or on a plasmid or vector.

The monocellular or multicellular organisms which are
10 obtained in accordance with the invention can be any cells which can be employed for biotechnological methods. These cells include, for example, fungi, yeast, bacteria and plant and animal cells. According to the invention, they are preferably transformed cells
15 of fungi, particularly preferably of fungi of the genus *Ashbya*. The species *Ashbya gossypii* is particularly preferred in this connection.

The invention is explained in more detail below with
20 the aid of examples without there being any intention of thereby limiting the subject matter to the examples:

The gene for isocitrate dehydrogenase (IDP3) was cloned by PCR and then sequenced (sequence, see Fig. 11). The
25 recombinantly-effected partial deletion of the gene by means of replacement mutagenesis using a geneticin resistance gene (Fig. 1) was confirmed by Southern blotting (Fig. 2). This disruption, i.e. destruction of the gene in the genome of the fungus, results in the
30 fungus no longer being able to form the isocitrate dehydrogenase which is encoded by the gene. Fig. 3 shows the decrease in enzyme activity in the disrupted strain AgADP3b as compared with the wild type ATCC 10895. It was possible to demonstrate in preparations
35 of the peroxisomes that this enzyme is located in these organelles (Fig. 10). Whereas the enzyme activity is clearly measurable in wild-type peroxisomes, there is

FZJ 9909 PCT

- 9 -

no longer any activity in the peroxisomes belonging to the disrupted strain.

The disruption of the gene results in a marked decrease
 5 in the formation of vitamin as compared with the parent strain (Fig. 4). By contrast, if the gene is introduced, in additional copy and under the control of the strong TEF promoter on a plasmid (Fig. 6), into the Ashbya cells, it is then possible to measure a marked
 10 increase in the activity of the enzyme and in the formation of riboflavin (Fig. 5).

Fig. 7 shows that NADPH is required as a reducing agent in the metabolism of unsaturated fatty acids in two out
 15 of three alternative reaction pathways. The 2,4-dienoyl-CoA reductase which is involved in this was also found to be located in peroxisomes in Ashbya cells (Fig. 8). Disruption of the IDP3 gene ought now to lead to a decrease in the growth of the cells on linoleic
 20 acid or linolenic acid. It was also possible to measure this (Fig. 9). This demonstrates that the importance of IDP3 for the metabolism of the cells lies in the formation of NADPH.

Description of the figures

- Fig. 1: Scheme for constructing the vector pIDPkan for replacing the chromosomal *AgIDP3* gene with a gene copy which has been rendered inactive by deletion and insertion of the G418^R gene.
- Fig. 2: Use of Southern blotting analysis to check the partial deletion and simultaneous insertion of the geneticin resistance cassette at the *AgIDP* locus. Genomic, *SphI*-cleaved DNA was hybridized with a digoxigenin-labelled probe.
- Fig. 3: Comparison of the enzymic activities of the NADP-specific ICDH from *Ashbya* wild type, from the mutant *A.g. ΔIDP3b* and from the *AgIDP* overexpressors *A.g. pAGIDP3a* and *A.g. pAGIDP3b* during growth on glucose complete medium.
- Fig. 4: Comparison of the growth of, and the formation of riboflavin by, the *Ashbya* wild type and the mutant *A.g. ΔIDP3b* during growth on soy-bean oil complete medium.
- Fig. 5: Comparison of the growth of, of the formation of riboflavin by, and of the NADP-specific ICDH of, the *Ashbya* wild type and the *AgIDP3* overexpressors *A.g. pAGIDP3a* and *A.g. pAGIDP3b* during culture on soy-bean oil complete medium.
- Fig. 6: Plasmid for overexpressing the *AgIDP3* gene under the control of the *TEF* promoter and *TEF* terminator.

In order to introduce the *SphI* cleavage site, it was necessary to change the nucleotide sequence encoding the second amino acid. This involved a conservative replacement of the amino acid glycine with leucine.

Fig. 7: Catabolic pathways in peroxisomes for unsaturated fatty acids having double bonds at even (A) and odd (B, C) carbon atoms in accordance with Henke et al. (1998).

Fig. 8 Separation of organelles isolated from *Ashbya* wild type in a Percoll density gradient:

Activities [U/ml] of the marker enzymes catalase (peroxisomes) and fumarase (mitochondria), of NAD-specific and NADP-specific ICDH and of the 2,4-dienoyl-CoA reductase and Δ^3, Δ^2 -enoyl-CoA isomerase which are required for catabolizing unsaturated fatty acids.

Fig. 9: Comparison of the radial growth of *Ashbya* wild type, of the mutants A.g. $\Delta IDP3a$ and A.g. $\Delta IDP3b$ and the overexpressors A.g. pAGIDP3a and A.g. pAGIDP3b on different fatty acids (A: 18:1 cis9; B: 18:2 cis9,12; C: 18:3 cis9,12,15).

Fig. 10: Distribution of the enzymes catalase and ICDH in a Percoll density gradient following centrifugation of organelles from the wild type mycelium (A) and the mutant A.g. $\Delta IDP3b$ mycelium (B).

FZJ 9909 PCT

- 12 -

Description of the sequence

Nucleotide sequence, and amino acid sequence deduced
5 therefrom, of the *A. gossypii* *AgIDP3* gene encoding the
peroxisomal NADP-specific isocitrate dehydrogenase.

We claim:

1. A monocellular or multicellular microorganism for
5 the biotechnological production of riboflavin,
which exhibits an activity of an NAD(P)H-forming
enzyme which is higher than that of a wild type of
the species *Ashbya gossypii* ATCC 10895.
- 10 2. A monocellular or multicellular microorganism as
claimed in claim 1, which exhibits an elevated
isocitrate dehydrogenase activity.
- 15 3. A monocellular or multicellular microorganism as
claimed in claim 1 or 2, which is a fungus.
4. A monocellular or multicellular microorganism as
claimed in any of claims 1 to 3, which is a fungus
from the genus *Ashbya*.
- 20 5. A monocellular or multicellular microorganism as
claimed in any of claims 1 to 4, which is a fungus
of the species *Ashbya gossypii*.
- 25 6. An isocitrate dehydrogenase gene having a
nucleotide sequence which encodes the amino acid
sequence given in Fig. 11 (SEQ ID No. 2) and its
allelic variations.
- 30 7. An isocitrate dehydrogenase gene as claimed in
claim 6 having the nucleotide sequence from
nucleotide 1 to nucleotide 1262 as depicted in
Fig. 11 (SEQ ID No. 1).
- 35 8. An isocitrate dehydrogenase gene as claimed in
claim 6 or 7 having an upstream promoter which
possesses the nucleotide sequence from nucleotide
-661 to -1 as depicted in Fig. 11 (SEQ ID No. 1).

9. A gene structure which contains an isocitrate dehydrogenase gene as claimed in any of claims 6 to 8 and also regulatory sequences which are operatively linked to this gene.
10. A vector which contains an isocitrate dehydrogenase gene as claimed in any of claims 6 to 8 or a gene structure as claimed in claim 9.
11. A genetically altered microorganism for the biotechnological production of riboflavin, harboring, in replicatable form, an isocitrate dehydrogenase gene as claimed in any of claims 6 to 8 which is more strongly expressed than in the corresponding microorganism which is not genetically altered and/or whose copy number is increased.
12. A genetically altered microorganism as claimed in claim 11 which harbors a gene structure as claimed in claim 9 or a vector as claimed in claim 10.
13. A genetically altered microorganism as claimed in claim 11 or 12 which harbors an isocitrate dehydrogenase which exhibits a catalytic activity which is increased, and/or an ability to be inhibited by inhibitors which is decreased, as compared with that of the corresponding microorganism which is not genetically altered.
14. A process for the biotechnological production of riboflavin, which comprises using a microorganism as claimed in any of claims 1 to 5 or 11 to 13.
15. A process for preparing a riboflavin-producing monocellular or multicellular organism, which comprises using recombinant methods to increase

the activity of an NAD(P)H-forming enzyme in comparison to that of a wild type of the species *Ashbya gossypii* ATCC 10895.

- 5 16. A process as claimed in claim 15, wherein the increase in enzyme activity is achieved by replacing the promoter and/or increasing the gene copy number.
- 10 17. A process as claimed in claim 15 or 16, wherein the enzymic activity is increased as a result of the catalytic activity of the isocitrate dehydrogenase being increased and/or the ability of the isocitrate dehydrogenase to be inhibited by
15 inhibitors being decreased.
18. The use of a microorganism as claimed in any of claims 1 to 5 and 11 to 13 for producing riboflavin.
- 20 19. The use of an isocitrate dehydrogenase gene as claimed in any of claims 6 to 8 for preparing a microorganism as claimed in any of claims 1 to 5 and 11 to 13.
- 25 20. The use of a gene structure as claimed in claim 9, or of a vector as claimed in claim 10, for preparing a microorganism as claimed in any of claims 1 to 5 and 11 to 13.

FZJ 9909 PCT

Abstract

The present invention relates to a monocellular or multicellular organism, in particular microorganism, for the biotechnological production of riboflavin, with the enzymic activity of this microorganism with regard to NAD(P)H formation being higher than that of a wild type of the species *Ashbya gossypii* ATCC10895.

FZJ 9909 PCT

1/10




Fig. 1

FZJ 9909 PCT

2/10




Fig. 2

FZJ 9909 PCT

3/10




Fig. 3

FZJ 9909 PCT

4/10




Fig. 4

FZJ 9909 PCT

5/10




Fig. 5

Fig. 6

Fig. 7

FZJ 9909 PCT

8/10




Fig. 8

FZJ 9909 PCT

9/10





Fig. 9

FZJ 9909 PCT

10/10




Fig. 10

Declaration, Power of Attorney

Page 1 of 4

0050/050572

We (I), the undersigned inventor(s), hereby declare(s) that:

My residence, post office address and citizenship are as stated below next to my name,

We (I) believe that we are (I am) the original, first, and joint (sole) inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Monocellular or multicellular organisms for producing riboflavin

the specification of which

☒ is attached hereto.

☐ was filed on _____ as

Application Serial No. _____

and amended on _____

☒ was filed as PCT international application

Number PCT/EP 00/07370

on 31 July 2000

and was amended under PCT Article 19

on _____ (if applicable).

We (I) hereby state that we (I) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We (I) acknowledge the duty to disclose information known to be material to the patentability of this application as defined in Section 1.56 of Title 37 Code of Federal Regulations.

We (I) hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s)

Application No.	Country	Day/Month/Year	Priority Claimed
19937548.8	Germany	09 August 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

pduspc001 - 25

We (I) hereby claim the benefit under Title 35, United States Codes, § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

We (I) hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.

Filing Date

**Status (pending, patented,
abandoned)**

And we (I) hereby appoint **Messrs. HERBERT. B. KEIL**, Registration Number **18,967**; and **RUSSEL E. WEINKAUF**, Registration Number **18,495**; the address of both being Messrs. **Keil & Weinkauff, 1101 Connecticut Ave., N.W., Washington, D.C. 20036** (telephone **202-659-0100**), our attorneys, with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to sign the drawings, to receive the patent, and to transact all business in the Patent Office connected therewith.

We (I) declare that all statements made herein of our (my) own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Declaration

Page 3 of 4

0050/050572

1-00

Henning Althöfer
NAME OF INVENTOR

Henning Althöfer
Signature of Inventor

Date 14.12.2001

Mainstr.12
67117 Limburgerhof DEX
Germany
Citizen of: Germany
Post Office Address: same as residence

2-00

Oskar Zelder
NAME OF INVENTOR

Oskar Zelder
Signature of Inventor

Date 14.12.2001

Roßmarktstr.27
67346 Speyer DEX
Germany
Citizen of: Germany
Post Office Address: same as residence

3-00

Jose L. Revuelta Doval
NAME OF INVENTOR

Jose L. Revuelta Doval
Signature of Inventor

Date 14.12.2001

Grillo 11 4E
37001 Salamanca ESX
Spain
Citizen of: Spain
Post Office Address: same as residence

4-00

Maria Angeles Santos Garcia
NAME OF INVENTOR

M. Angeles Santos Garcia
Signature of Inventor

Date 14.12.2001

C/Escuelas 1-5
37001 Salamanca ESX
Spain
Citizen of: Spain
Post Office Address: same as residence

10044555 002400

Declaration

Page 4 of 4

0050/050572

5-00 Hermann Sahn
NAME OF INVENTOR

Hermann Sahn
Signature of Inventor

Date
14.12.2001

Wendelinusstr. 71
52428 Jülich DEX
Germany
Citizen of: Germany
Post Office Address: same as residence

6-00 Klaus-Peter Stahmann
NAME OF INVENTOR

Klaus-Peter Stahmann
Signature of Inventor

Date
14.12.2001

Wilhelmstr. 20
52428 Jülich DEX
Germany
Citizen of: Germany
Post Office Address: same as residence

7-00 Ines Maeting
NAME OF INVENTOR

Ines Maeting
Signature of Inventor

Date
14.12.2001

Wiesenstr. 3
52428 Jülich DEX
Germany
Citizen of: Germany
Post Office Address: same as residence

FZJ 9909 PCT

11.13.2000

1/3

SEQUENCE LISTING

<110> BASF AG, Forschungszentrum [Research Center] Jülich GmbH
<120> Monocellular or multicellular organisms for producing riboflavin
<130> FZJ9909PCT
<140> PCT/EP00/07370
<141> 2000-07-31
<160> 2
<170> PatentIn Ver. 2.1
<210>
<211> 2321
<212> DNA
<213> Fungus of the species Ashbya Gossypii

<400> 1
ctgcagcaaa tcgaggtgat cgccaacgag gtggacgtgc ggcaggacgg gacctggtgc 60
atccggtacc gcgacgagtc cgagcacggg cagcacaagt cgcggtcgat cgcggcgtgc 120
aagcagcgct ggcaaacact cgagcccgcg ccggtgtatt tctactgagg cgatgggac 180
agcgacctga gcgctgcgaa ggaatgcgac ctgctgtttg cgaagagtgg caaggacctg 240
atctccttct gcaagaagca ggacgttccg ttccgcgagt tcaaacacttt tgacgatgtg 300
ctgagcgagg tcaagcgagt ggtggcgggc gaggcctctg tcacggaact ccaggggggc 360
tccgctgcgt aagcactgtc tgcacagtg accttggcgg tagctgcgat ttgtaactac 420
ctacgtaatt agtctgtctc gcgctgcggt ccagtgcctag gcaagcccca catgaaaggc 480
agccgtaagc aattagtaac ggcctagtag ggctccgatg tatgtgctag cacatgacag 540
cccaacgggt tgagaagtcc ggctcgaatc atttccgcgc cgagtgggtc gtgggtggag 600
ccgcccagacc ccttgtcagc gcgggcagtt ggatataagg cagtgggtgt agcaaaagtg 660
agXtgcgtgca ttacacgaag ccgagcgcaa caacgcacag acatcagtaa gcagct atg 720
Met
1

ggc aag gtg aag gta caa caa ccc atc gtc gag atg gac ggc gac gaa 768
Gly Lys Val Lys Val Gln Gln Pro Ile Val Glu Met Asp Gly Asp Glu
5 10 15
cag acg cgg atc atc tgg cac ttg atc aag gat cag etc atc ttc ccc 816
Gln Thr Arg Ile Ile Trp His Leu Ile Lys Asp Gln Leu Ile Phe Pro
20 25 30

tac ttg gac gtg gac ttg aag tac tac gat ctt tcc att gag aac agg 864
 Tyr Leu Asp Val Asp Leu Lys Tyr Tyr Asp Leu Ser Ile Glu Asn Arg
 35 40 45

gat gcc acc gag gac cgc gtg act gtg gag tct gcg gag gcg acc ctc 912
 Asp Ala Thr Glu Asp Arg Val Thr Val Glu Ser Ala Glu Ala Thr Leu
 50 55 60 65

aag tac ggc gtt gcc gtc aag tgt gcg att att acc ccg gac gag gcg 960
 Lys Tyr Gly Val Ala Val Lys Cys Ala Ile Ile Thr Pro Asp Glu Ala
 70 75 80

cgt gtc gag gag ttc ggg ctc aag gag atg tgg aag tct ccc aac ggg 1008
 Arg Val Glu Glu Phe Gly Leu Lys Glu Met Trp Lys Ser Pro Asn Gly
 85 90 95

acc atc cgg aac atc ctc ggc ggg acc gtc ttc aga gag ccc att att 1056
 Thr Ile Arg Asn Ile Leu Gly Gly Thr Val Phe Arg Glu Pro Ile Ile
 100 105 110

atc cca agg atc ccc aga ctg gtg ccc ggc tgg aac gag ccg atc att 1104
 Ile Pro Arg Ile Pro Arg Leu Val Pro Gly Trp Asn Glu Pro Ile Ile
 115 120 125

gtc ggc aga cac gcg ttt ggg gac cag tac aag gcg acc gac gtt gtc 1152
 Val Gly Arg His Ala Phe Gly Asp Gln Tyr Lys Ala Thr Asp Val Val
 130 135 140 145

att cca ggc gag ggc acg ttg aag ctg gtc ttt gaa agc aag gac ggg 1200
 Ile Pro Gly Glu Gly Thr Leu Lys Leu Val Phe Glu Ser Lys Asp Gly
 150 155 160

gac aag tcc aag aat ctt gac ctg gag ttc ttt gaa tac ccc aag gat 1248
 Asp Lys Ser Lys Asn Leu Asp Leu Phe Phe Glu Tyr Pro Lys Asp
 165 170 175

ggc ggt gtt gcc atg acc atgtactaca ccaccgactc gatcaccggc 1296
 Gly Gly Val Ala Met Thr
 180

tttgccaaagt cgagcttcga gttggcgcttg caaagaaaga tgccgctata ttcgacaacg 1356

aagaacacga tcttgaagaa gtacgacggc aagtttaagg atattttcga gggcatgtac 1416

ccagcggagt acaaggagaa gtttgaggct gctggcatct ggtatgaaca cagactgatt 1476

gacgatatgg ttgcgcagat gttgaagtcc aagggcggct tcatcattgc catgaagaac 1536

tacgatggtg atgtgcagtc ggacatcgtc gccagggtc tcgggtcttt gggctctcatg 1596

acttctgttc ttgtgtctcc agatggaaaag accttcgaga gtgaggccgc acatggcact 1656

gtcacccggc actacagaca gcaccagcag ggcaaggaaa catccaccaa ctctattgcc 1716

tctatttttg cctggatgcg cggtattata cacagaggta aggtcgacgg taccacagat 1776

gtcgtgaagt tcggcgagtt gttggagaag tccaccctgg acacgggtgca ggaggacatc 1836

atgaccaagg acctagcgtt gatcttgggc aagaccgaca gagccagcta tggtaccacg 1896

```
<400> 2
Met Gly Lys Val Lys Val Gln Gln Pro Ile Val Glu Met Asp Gly Asp
  1                    5                      10                     15

Glu Gln Thr Arg Ile Ile Trp His Leu Ile Lys Asp Gln Leu Ile Phe
      20                        25                       30

Pro Tyr Leu Asp Val Asp Leu Lys Tyr Tyr Asp Leu Ser Ile Glu Asn
    35                40

Arg Asp Ala Thr Glu Asp Arg Val Thr Val Glu Ser Ala Glu Ala Thr
   50                  55                   60

Leu Lys Tyr Gly Val Ala Val Lys Cys Ala Ile Ile Thr Pro Asp Glu
  65              70             75            80

Ala Arg Val Glu Glu Phe Gly Leu Lys Glu Met Trp Lys Ser Pro Asn
        85                 90

Gly Thr Ile Arg Asn Ile Leu Gly Gly Thr Val Phe Arg Glu Pro Ile
     100               105           110

Ile Ile Pro Arg Ile Pro Arg Leu Val Pro Gly Trp Asn Glu Pro Ile
    115                 120         125

Ile Val Gly Arg His Ala Phe Gly Asp Gln Tyr Lys Ala Thr Asp Val
   130              135          140

Val Ile Pro Gly Glu Gly Thr Leu Lys Leu Val Phe Glu Ser Lys Asp
  145                150          155           160

Gly Asp Lys Ser Lys Asn Leu Asp Leu Glu Phe Phe Glu Tyr Pro Lys
      165                170           175

Asp Gly Gly Val Ala Met Thr
    180
```